Literature DB >> 23619104

Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing.

Margaret Gleeson1, Bettina Meiser, Kristine Barlow-Stewart, Alison H Trainer, Kathy Tucker, Kaaren J Watts, Michael Friedlander, Nadine Kasparian.   

Abstract

PURPOSE/
OBJECTIVES: To identify women's information and communication preferences about treatment-focused genetic testing (TFGT) in the ovarian cancer context. RESEARCH APPROACH: A qualitative interview study.
SETTING: Two familial cancer services and a gynecologic oncology clinic at a major teaching hospital in Australia. PARTICIPANTS: 22 women diagnosed with ovarian cancer who had either advanced disease and had previously undergone TFGT (n = 12) or had been diagnosed in the previous 6-20 weeks with ovarian cancer and had not undergone TFGT (n = 10). METHODOLOGIC APPROACH: Participants were interviewed individually about actual and hypothetical views of TFGT. The interviews were transcribed and organized into themes using qualitative analysis software.
FINDINGS: Most women wanted to be informed about TFGT prior to their surgery for ovarian cancer. The majority preferred to receive the information verbally; slightly more women preferred their medical oncologist to deliver the information compared to a genetic specialist or oncology nurse. Women preferred the focus of pretest information to be on them and their treatment.
CONCLUSIONS: Women diagnosed with ovarian cancer want information about genetic testing early with focus placed on the potential benefits of genetic testing on treatment.
INTERPRETATION: The findings of this study provide much-needed guidance to oncology nurses and other oncology healthcare professionals about when, what, and how information about TFGT should be delivered to patients diagnosed with ovarian cancer. Supportive patient education materials now need to be developed to assist these women in making informed decisions about genetic testing. KNOWLEDGE TRANSLATION: Knowing that women do want TFGT, how they want it presented and by whom, and the content and level of detail that women want means that TFGT can now be presented as an option to women newly diagnosed with ovarian cancer, which may influence firstline treatment. The findings also provide the knowledge required to prepare education tools to assist oncology nurses involved in frontline care.

Entities:  

Mesh:

Year:  2013        PMID: 23619104     DOI: 10.1188/13.ONF.40-03AP

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  14 in total

1.  Health professionals' evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer.

Authors:  Kirsten F L Douma; Bettina Meiser; Judy Kirk; Gillian Mitchell; Christobel Saunders; Belinda Rahman; Mariana S Sousa; Kristine Barlow-Stewart; Margaret Gleeson; Kathy Tucker
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

2.  Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.

Authors:  Hannah Shipman; Samantha Flynn; Carey F MacDonald-Smith; James Brenton; Robin Crawford; Marc Tischkowitz; Nicholas J Hulbert-Williams
Journal:  J Genet Couns       Date:  2017-05-24       Impact factor: 2.537

3.  Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.

Authors:  Rachel A Pozzar; Fangxin Hong; Niya Xiong; Jill E Stopfer; Manan M Nayak; Meghan Underhill-Blazey
Journal:  Fam Cancer       Date:  2021-03-10       Impact factor: 2.375

4.  How, who, and when: preferences for delivery of genome sequencing results among women diagnosed with breast cancer at a young age.

Authors:  Kimberly A Kaphingst; Jennifer Ivanovich; Ashley Elrick; Rebecca Dresser; Cindy Matsen; Melody S Goodman
Journal:  Mol Genet Genomic Med       Date:  2016-10-24       Impact factor: 2.183

Review 5.  Communication Needs of Cancer Patients and/or Caregivers: A Critical Literature Review.

Authors:  Jieyu Li; Xingjuan Luo; Qian Cao; Yi Lin; Yinghua Xu; Qiuping Li
Journal:  J Oncol       Date:  2020-05-07       Impact factor: 4.375

6.  Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing.

Authors:  Sarah Wright; Mary Porteous; Diane Stirling; Julia Lawton; Oliver Young; Charlie Gourley; Nina Hallowell
Journal:  J Genet Couns       Date:  2018-05-11       Impact factor: 2.537

Review 7.  Communication about genetic testing with breast and ovarian cancer patients: a scoping review.

Authors:  Chris Jacobs; Christine Patch; Susan Michie
Journal:  Eur J Hum Genet       Date:  2018-12-20       Impact factor: 4.246

8.  Identifying Needs: a Qualitative Study of women's Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study.

Authors:  Mirjam Tonheim Augestad; Hildegunn Høberg-Vetti; Cathrine Bjorvatn; Ragnhild Johanne Tveit Sekse
Journal:  J Genet Couns       Date:  2016-07-28       Impact factor: 2.537

Review 9.  Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.

Authors:  Jeanna M McCuaig; Tracy L Stockley; Patricia Shaw; Michael Fung-Kee-Fung; Alon D Altman; James Bentley; Marcus Q Bernardini; Beatrice Cormier; Hal Hirte; Katharina Kieser; Andree MacMillan; Wendy S Meschino; Karen Panabaker; Renee Perrier; Diane Provencher; Kasmintan A Schrader; Kimberly Serfas; Eva Tomiak; Nora Wong; Sean S Young; Walter Henri Gotlieb; Paul Hoskins; Raymond H Kim
Journal:  J Med Genet       Date:  2018-07-24       Impact factor: 6.318

Review 10.  A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

Authors:  Luca Falzone; Giuseppa Scandurra; Valentina Lombardo; Giuseppe Gattuso; Alessandro Lavoro; Andrea Benedetto Distefano; Giuseppe Scibilia; Paolo Scollo
Journal:  Int J Oncol       Date:  2021-06-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.